Aeovian Pharmaceuticals
Financing Round
- Series B
Round Led or Co-led By SymBiosis
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted, highly selective small-molecule inhibitors of mTORC1 and CD38 to restore cellular metabolic quality control in rare genetic and age-related diseases. Its lead candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor in Phase 1 development for seizures associated with tuberous sclerosis complex (TSC) refractory epilepsy, with additional mTORC1 and CD38 programs advancing through the pipeline.
